Heron Bay Capital Management Has $6.33 Million Stock Position in Zoetis Inc. $ZTS

Heron Bay Capital Management raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 36.2% in the third quarter, HoldingsChannel.com reports. The firm owned 43,224 shares of the company’s stock after purchasing an additional 11,490 shares during the quarter. Zoetis accounts for approximately 1.2% of Heron Bay Capital Management’s portfolio, making the stock its 28th biggest holding. Heron Bay Capital Management’s holdings in Zoetis were worth $6,325,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Halbert Hargrove Global Advisors LLC increased its position in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares during the period. NewSquare Capital LLC boosted its position in Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the last quarter. Financial Consulate Inc. acquired a new stake in Zoetis during the 3rd quarter worth about $39,000. SJS Investment Consulting Inc. raised its position in shares of Zoetis by 1,606.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after acquiring an additional 257 shares in the last quarter. Finally, TruNorth Capital Management LLC acquired a new position in shares of Zoetis in the 3rd quarter valued at about $42,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on ZTS shares. HSBC set a $140.00 target price on Zoetis in a research note on Wednesday, December 10th. Morgan Stanley set a $160.00 price objective on shares of Zoetis in a research note on Thursday, December 18th. Barclays assumed coverage on shares of Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price on the stock. UBS Group set a $136.00 price target on shares of Zoetis in a report on Thursday, January 29th. Finally, Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Zoetis presently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

Shares of ZTS stock opened at $122.06 on Friday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The firm has a fifty day simple moving average of $126.16 and a two-hundred day simple moving average of $133.42. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.00. The firm has a market capitalization of $51.53 billion, a PE ratio of 20.28, a price-to-earnings-growth ratio of 1.92 and a beta of 0.95.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period last year, the firm earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is currently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.